The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

The recruitment status of this study is unknown because the information has not been verified recently.

Verified October 2013 by Meir Medical Center.
Recruitment status was Recruiting

Sponsor:

Information provided by (Responsible Party):

Meir Medical Center

ClinicalTrials.gov Identifier:

NCT01809574

First received: March 10, 2013

Last updated: April 8, 2015

Last verified: October 2013

History of Changes

Purpose

We hypothesized that the multi-disciplinary assessment of interstitial lung disease patients would lead to a more accurate diagnosis and consequently alterations in treatment regimens that may lead to improved outcomes.

Condition
Interstitial Lung Disease Idiopathic Pulmonary Fibrosis Connective Tissue Disease


Study Type:	Observational
Study Design:	Observational Model: Cohort Time Perspective: Prospective
Official Title:	The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease

Resource links provided by NLM:

Genetics Home Reference related topics: idiopathic pulmonary fibrosis pulmonary alveolar microlithiasis

MedlinePlus related topics: Connective Tissue Disorders Interstitial Lung Diseases Lung Diseases Pulmonary Fibrosis

Genetic and Rare Diseases Information Center resources: Idiopathic Pulmonary Fibrosis

U.S. FDA Resources

Further study details as provided by Meir Medical Center:

Primary Outcome Measures:

The number of patients with collagen related pulmonary fibrosis that are diagnosed by Rheumatologists compared to Pulmonologists. [ Time Frame: two years ] [ Designated as safety issue: No ]


Estimated Enrollment:	60
Study Start Date:	May 2013
Estimated Study Completion Date:	March 2016
Estimated Primary Completion Date:	March 2016 (Final data collection date for primary outcome measure)

Eligibility


Ages Eligible for Study:	18 Years and older (Adult, Senior)
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

60 patients that will refer to the pulmonary outpatient or inpatients department for evaluation due to ILD will be included

Criteria

Inclusion Criteria:

Age above 18 years old
ILD according to ATS/ERS guidelines
Signed inform consent

Exclusion Criteria:

Previous lung surgery
Other significant systemic disease

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01809574

Contacts


Contact: David Shitrit, Dr.	097471556	davids3@clalit.org.il

Locations


Israel
Meir Medical Center	Recruiting
Kfar Saba, Israel, 972
Contact: David Shitrit, Dr 09-7471556 davids3@clalit.org.il

Sponsors and Collaborators

Meir Medical Center

Investigators


Principal Investigator:	David Shitrit, Dr	Head of Pulmonary departmant, Meir Medical Center.

More Information


Responsible Party:	Meir Medical Center
ClinicalTrials.gov Identifier:	NCT01809574 History of Changes
Other Study ID Numbers:	225-12-MMC
Study First Received:	March 10, 2013
Last Updated:	April 8, 2015
Health Authority:	Israel: Ethics Commission

Keywords provided by Meir Medical Center:


Interstitial lung disease Idiopathic pulmonary fibrosis Connective tissue disease

Additional relevant MeSH terms:


Fibrosis Lung Diseases Idiopathic Pulmonary Fibrosis Idiopathic Interstitial Pneumonias Pulmonary Fibrosis	Lung Diseases, Interstitial Connective Tissue Diseases Pathologic Processes Respiratory Tract Diseases

ClinicalTrials.gov processed this record on September 29, 2016

To Top